Ligand(LGND) - 2025 Q4 - Earnings Call Transcript

Financial Performance - Ligand Pharmaceuticals reported total GAAP revenue of $268 million for 2025, up from $167 million in 2024, with core revenue at $240 million reflecting a 43% year-over-year growth [15][16] - Full-year royalty revenue grew to $161 million, an increase of 48% year-over-year, driven by products such as FILSPARI, Ohtuvayre, CAPVAXIVE, and QARZIBA [15][16] - Adjusted EPS increased to $8.13, up 42% year-over-year, indicating strong operating leverage and higher royalty contributions [15][16] Business Line Performance - FILSPARI's U.S. net sales reached $103 million in Q4, representing 108% growth year-over-year, with total global sales of approximately $355 million for 2025 [16][17] - Ohtuvayre reported net sales of $178 million in Q4, with full-year sales of $506 million, marking a strong launch in COPD history [17][34] - CAPVAXIVE's net sales were $279 million in Q4 and $755 million for the full year, nearing blockbuster status [17][18] Market Performance - Ligand's royalty portfolio is expected to see a 23% compound annual growth rate in royalty receipts from 2025 through 2030, driven by contributions across the entire portfolio [12][13] - The company anticipates significant commercial opportunities in Japan for FILSPARI, with a sizable market for IgAN [71] Company Strategy and Industry Competition - Ligand is focusing on disciplined investments to create new royalty streams and enhance long-term shareholder value, with a systematic portfolio management strategy to drive value across partnerships [9][10][22] - The demand for royalty financing has doubled over the last five years, positioning Ligand favorably within the biopharmaceutical royalty financing sector [10][11] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing strong trial results for QTORIN rapamycin and the successful partnership with Leona Bio for lasofoxifene [36] - The company is optimistic about the upcoming year, expecting multiple catalysts from its late-stage development pipeline [36][31] Other Important Information - Ligand ended 2025 with $734 million in cash equivalents and short-term investments, totaling over $1 billion in deployable capital [20] - The company reaffirmed its 2026 financial guidance, expecting adjusted EPS of approximately $8-$9 per share and royalty revenue of $200 million-$225 million [20][21] Q&A Session Summary Question: Clinical update expectations for late-stage royalty portfolio - Management highlighted several active late-stage programs, including QARZIBA and TZIELD, with robust updates expected in the coming quarters [39][40] Question: Update on monetizing older assets in the portfolio - Management confirmed active engagement in 5 to 10 opportunities for older assets, with potential announcements expected by year-end [43][44] Question: Larger opportunity for TZIELD and peak sales size - Management acknowledged TZIELD's low royalty but emphasized its potential blockbuster status, particularly with the upcoming Stage 3 indication [48][50] Question: Impact of FSGS approval delay on 2026 outlook - Management indicated that the FSGS contribution to 2026 guidance is modest, with a risk-adjusted estimate of $4 million [53][55] Question: Changes in selection criteria for potential partnerships - Management noted that as the portfolio value grows, the average deal size will increase, focusing on high clinical value assets [58][59]